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Solidified reverse micellar solutions (SRMS) are reverse micelles containing lecithin and a triglyceride, 
for example, SOFTISAN
®
142, which is hydrogenated coco glyceride. SRMS transform into a lamellar 
mesophase after melting on contact with water; this transformation enables controlled release of 
solubilized drugs. They offer potentials for sustained drug delivery of both hydrophilic and lipophilic 
drugs. SRMS have the advantage of providing more flexibility in controlling the drug release and 
protecting the encapsulated ingredients from chemical degradation. SRMS based systems influence the 
absorption of active ingredients through different mechanisms to modify the release of active 
ingredients, and improve drugs bioavailability. The types of SRMS-based drug delivery systems include 
solid lipid nanoparticles (SLN), solid lipid microparticles (SLM), tablets and suppositories amongst 
others. The work exhaustively reviews the advances in SRMS based carriers. Its formulation methods, 
characterisation and delivery systems were discussed in details. 
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There is growing interest and investment in the use of 
lipid-based systems in drug discovery and product deve-
loppment to effectively overcome physical and biological 
barriers related to poor aqueous solubility and stability, 
membrane permeability, drug efflux and availability (We-
stesen and Siekmann, 1998). Solid lipids have the advan-
tage of providing more flexibility in controlling the drug 
release and protecting the encapsulated ingredients from 
chemical degradation. Also, they allow for the incorpora-
tion of hydrophilic as well as hydrophobic drugs (Lippa-
cher et al., 2001; Hu et al., 2020). Many waxes (for exam-
ple, stearic acid, mono-, di- and tri-glycerides, glyceryl 
behenate, glyceryl monostearate, hydrogenated castor 
oil, among others) have been extensively investigated for 
sustaining the release of various drugs (Wadher et al., 
2010).  
Reverse micellar solutions (RMS) are lipidic solutions 
consisting of lecithin (30% w/w) dissolved in an oily
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vehicle, for example, isopropylmyristate or middle-chain 
trigly-cerides and transform into a lamellar mesophase on 
contact with water (Papantoniou and Müller-Goymann, 
1995; Friedrich et al., 2000). This application-induced 
transformation into a semisolid system of liquid crystals 
enables controlled release of solubilized drugs (Müller-
Goymann and Hamann, 1993; Schneeweis and Müller-
Goymann, 1997; Friedrich and Müller-Goymann, 2003). 
On contact with water, the liquid reverse micelles (LRMS) 
exhibits an application induced transformation into a 
semi-solid system of liquid crystalline microstructure. The 
structure of the liquid crystal has been identified by pola-
rized light microscopy as a lamellar mesophase (Friedrich 
and Müller-Goymann, 2003). Solidified reverse micellar 
solutions (SRMS) are reverse micelles containing lecithin 





 154, which is a completely hydrogenated 
palm oil. SRMS offer potentials for sustained drug deli-
very of both hydrophilic and lipophilic drugs and also 
transform into a lamellar meso-phase after melting on 
contact with water. This trans-formation enables con-
trolled release of solubilized drugs. Both LRMS and 
SRMS offer a high solubilization rate of different types of 
drugs (Friedrich and Müller-Goymann, 2003). SRMS 
based carriers have been investigated, and successfully 
employed to achieve controlled release of hydrophilic and 
lipophilic drugs (Schneeweis and Müller-Goymann, 2000; 
Friedrich and Müller-Goymann, 2003; Umeyor et al., 
2012 a; Chime et al., 2012; Chime et al., 2013a,b). 
SRMS can also be formed using modified natural lipids 
containing lecithin and dika wax (Chinaeke et al., 2013), 
lecithin and Moringa oil, lecithin and goat fats (Uronnachi 
et al., 2013), lecithin and beeswax (Momoh et al., 2012) 
and lecithin and soy oil respectively at the ratios that 
could yield SRMS (Chinaeke et al., 2013). 
SRMS were believed to be formed by combination of 
lecithin (30%) and oily vehicle or triglycerides (60 - 70%) 
(Schneeweis and Müller-Goymann, 2000). However, 
Friedrich and Müller-Goymann (2003), Umeyor et al. 
(2012 a), Momoh et al. (2012) Uronnachi et al. (2013) 
and Chime et al. (2013) demonstrated respectively that 
SRMS could be formed using 1:1, 2:1, 1:2, 3:1 and 2:3 
ratios of lecithin and solid fats.  
Most lipid based formulations today are available as 
normal release formulations, and this poses serious pro-
blems of patient noncompliance leading to poor disease 
management. This led to research into the field of 
controlled lipid based delivery system with huge success 
recorded by the discovery of SRMS. SRMS offer high 
solubilization capacities for different types of drugs in 
contrast with simple triglyceride systems (Friedrich and 
Muller-Goymann, 2003). However, the increase in water 
content causes a change in shape and size and finally a 
phase transformation from the reverse micellar solution 
into a lamellar liquid crystal. Solubilization of the drug in 
its free acid form results in almost spherical micelles, 
while solubilization of drug in its sodium salt form results 




in cylindrical micelles. The lamellar liquid crystals which 
form on contact with aqueous media can be used for 
sustained release, as the diffusion coefficient of the drug 
within the liquid crystals is smaller by factor 100 than that 
within an oily solution. The apparent diffusion coefficient 
of the drug depends on the thickness of the liquid 
crystalline interface which is also influenced when either 
the free acid or the salt is solubilized in the system 
(Muller-Goymann and Hamann, 1993). 
Lipid-based formulations and SRMS based systems 
influence the absorption of active ingredients through 
different mechanisms to modify the release of active 
ingredients, improve drugs bioavailability, stimulate the 
lymphatic transport of active ingredients, and interact with 
enterocyte based transport (Fouad et al., 2011). SRMS-
based formulations have been shown to enhance the 
bioavailability of drugs administered orally in addition to 
controlling the rate of drug release and have been used 
for once daily sustained release formulations (Umeyor et 
al., 2012a, Nnamani et al., 2010; Chime et al., 2013, 
Momoh et al., 2012, Uronnachi et al., 2013). The proven 
safety (GRAS) of lipid based carriers makes them 
attractive candidates for the formulation of pharma-
ceuticals (Attama and Nkemnele, 2005; Attama et al., 
2009). Lipid formulations in general, provide increased 
drug solubilization for water - insoluble drugs. If the drug 
is dissolved in the lipid matrix (for example, SRMS), the 
drug absorption is observed to be better. Drug suspen-
ded in the lipid matrix has been shown to get absorbed 
better than the conventional solid dosage forms (Sarkar, 
2002; Hou et al., 2003; Gao et al., 2004; You et al., 2005; 
Obitte et al., 2012; Brown et al., 2013). This could be due 
to the ease of wetting of the hydrophobic drug particles in 
the presence of lipid matrix. The presence of surfactant in 
the formulation may ease the wetting further. Also entra-
pment of drug in the micelles may be enhanced due to 
the presence of lipid matrix (Joshi and Shah, 2008). For 
poorly water soluble drug molecules, whose dissolution in 
water is likely the rate limiting step to overall oral absor-
ption, the primary role of ingested lipids and their lipolytic 
products is to impact the drug dissolution step by forming 
different colloidal particles with bile components, which 
are able to maintain a larger quantity of hydrophobic 
drugs in solution via micellar solubilization (Porter, 2007). 
The primary mechanism of action which leads to im-
proved bioavailability is usually avoidance or partial avoi-
dance of slow dissolution process which limits the 
bioavailability of hydrophobic drugs from conventional 
solid dosage form (Pouton, 2000). Lipid-based excipients 
such as glycerides, fatty acids, ionic and non-ionic sur-
factants are known permeability enhancers (Aungst et al., 
1996; Kuentz, 2012), which may be due to increased 
membrane fluidity. Permeability enhancement may also 
be achieved by the interaction of lipid based drug delivery 
system (LDDS) with efflux transporters. A well-known 
efflux transporter at the apical membrane of human 
intestine   is   the  P-glycoprotein  (P-gp).  Excipients  with 




inhibiting effects on efflux pumps are found in the group 
of medium chain glycerides, polyethylene glycols, poly-
sorbates and polyethoxylated castor oil or block copo-
lymers of the type Pluronic. Surfactants have been shown 
to inhibit P-gp because of their amphiphilic structure 
(Bogman et al., 2003; Aungst et al., 1996; Pang et al., 
2007; Kuentz, 2012). 
 
 
MATERIALS USED FOR SRMS FORMULATION 
 
Basically, SRMS are formed mainly using lecithin (for 
example, Phospholipon
®
 90G, a purified soybean lecithin 
with at least 90% (w/w) phosphatidylcholine, phospho-
lipon
®
 90H, completely hydrogenated soybean lecithin 
with at least 90% (w/w) phosphatidylcholine) and a trigly-
cride (softisan
®
 100, 133, 134, 138, 142, a hydroge-nated 
coco-glycerides and softisan
®
 154, a hydrogenated palm 
oil) at ratios 1:1, 1:2 and 2:1 (Friedrich and Müller-
Goymann, 2003; Umeyor et al., 2012; Chime et al., 
2013). Oils like soy oil, isopropyl myristate, coco nut oil 
and Moringa could be used in the right ratio in formulating 
SRMS (Schneeweis and Müller-Goyman, 2000; Chinaeke 
et al., 2013). Some waxes like bees wax, dika wax and 
fats from animals for example, goat fat may also be used 
in the formulation of SRMS (Momoh et al., 2012; 
Uronnachi et al., 2013). 
 
 
FORMULATION OF SRMS 
 
SRMS are normally formulated by fusion using a 
magnetic stirrer hot plate. A binary mixture (usually, 1:1, 
1:2 and 2:1) of lecithin and triglycerides for example, 
softisan, respectively are normally used for SRMS 
preparation. The lipids are melted together and stirred 
with a Teflon coated magnet at a temperature of about 60 
- 90°C, depending on the SRMS composition. The molten 
lipids are stirred until a transparent melt is obtained. 
Then, the homogeneous mixture will be stirred at room 




CHARACTERISATION OF SRMS 
 
Differential scanning calorimetric analysis 
 
Melting transitions and changes in heat capacity of the 
SRMS could be determined using a differential scanning 
calorimeter. About 1-5 mg of SRMS could be placed in 
the aluminum pan, hermetically sealed and the thermal 
behaviour determined in the range of 10-190°C at a 
heating rate of 5 or 10°C/min (Nnamani et al., 2010; 
Umeyor et al., 2012 a).  
Depending on a variety of factors, lipids may exist in one 





crystal modifications. Lipids are polymorphic and trans-
form systematically through a series of successive 
crystalline forms without change in chemical structure 
(O’Brien, 1998). The polymorphic transitions may be 
influenced by the addition of one or more substances (or 
other fats) to the SRMS (Attama et al., 2006). Conse-
quently, certain properties necessary for improved perfor-
mance as drug delivery bases may be influenced. It is 
important to know the thermal characteristics, crystal 
habit, texture, and appearance of a new lipid matrix when 
determining its suitability for use in certain food or phar-
maceutical application. DSC is the most widely used 
thermo-analytic technique for studying lipids and their 
mixtures. It gives information about the temperatures and 
energy associated with their fusion and crystallization, 
phase behavior, polymorphic transformations, and data to 
estimate solid fat contents (Tan et al., 2000; Solís-
Fuentes et al., 2005; Attama et al., 2006). Figure 1 shows 
the DSC thermograms of SRMS 100 (lecithin softisan 
100 mixtures), (b) SRMS 142 (lecithin S142 mixtures, 
with 0, 30, 40, 50 and 60% (w/w) bottom to top) (Friedrich 
and Müller-Goymann, 2003). The crystallinity index (CI%) 
of the SRMS could be calculated using the Equation (1) 














 100 fPL                             1 
 
           (1) 
 
Where, enthalpyPL is the fusion enthalpy of pure lipid for 
example, softisan, enthalpySRMS is the fusion enthalpy of 
the lipid matrix admixture (SRMS) and fPL is a correction 
factor which takes into account the concentration of pure 
lipid. The SRMS with lower CI are preferable due to 
presence of spaces in the SRMS for drug localization 
therefore, leading to high payload of drug. 
 
 
Wide angle X-ray diffraction analysis (WAXD) 
 
WAXD analysis of lipid matrices gives information on the 
crystalline state of the matrices, as it reveals the 
dimensions of the short spacing of the unit cells. WAXD 
analysis gives further insights on the preferred orientation 
and crystallinity of the samples with emphasis on the 
orderliness of the crystal arrangement (preferred 
orientation) and the ratio of the crystalline properties to 
the non-crystalline properties (Attama et al., 2006). 
Distorted crystal arrangements of the individual lipids 
within the SRMS are desirable in order to create spaces 
for drug localization. This is a desirable quality in parti-
culate drug delivery systems since it enhances the drug 
loading capacity of the lipids and also improves the 
overall drug encapsulation efficiency. Figure 2 shows the 
WAXD diffractograms of SRMS 142 consisting softisan 
142  and  60%  P90G  (Friedrich  and  Müller-Goymann,






Figure 1. DCS thermograms of (a) SRMS 100 (lecithin S100 mixtures) and (b) SRMS 142 (lecithin S142 mixtures, with 0, 30, 40, 
50 and 60% (w/w) bottom to top), S: softisan
®










































Figure 2. WAXD diffractograms of SRMS 142 consisting softisan 142 and 60% P90G (Friedrich and Müller-Goymann, 2003). 































Figure 3. SAXD differactograms of different batches of lipid matrices formulated with different ratios of P90G and dika fats; 




2003). The interlayer spacing in the SRMS may be 




𝑛𝜆 = 2𝑑 sinθ                    2                                             
                                                             (2)                        
 
Where, λ is the wavelength of the incident X-ray beam, n 
is  a  positive  integer  which  describes  the  order  of  the 
interference and θ is the scattering angle. The parameter 
d, otherwise called the interlayer spacing, is the separa-
tion between a particular set of planes of the crystal 
lattice structure (Attama et al., 2006). 
 
 
Small angle X-ray diffraction analysis (SAXD) 
 
SAXD is used to analyze the long range order of the 
crystalline structure of the lipid matrices. Interlayer spa-
cing is the separation between a particular set of planes 
of the crystal lattice structure (Attama and Müller-
Goymann, 2006). Many lipids are known to arrange 
themselves in layered structures with a repeat distance of 
few nanometers, thus giving rise to Bragg reflections in 
the small angle region. The repeat distances correspond 
to the thickness of the lipid layers
 
(Attama et al., 2006). If 
the diffractograms produced by the SRMS are lamellar, it 
shows that the crystal arrangements of the individual 
lipids were disorganized. Lipid matrices with a certain 
degree of disorder are considered to be ideal for formu-
lation of microparticulate lipid carriers due to their high 
active ingredient payload capacity (Attama et al., 2006; 
Attama and Muller-Goymann, 2007). Figure 3 shows the 
SAXD diffractograms of SRMS formulated with Phospho-
lipon 90G and dika wax (Chinaeke et al., 2013). 
 
 
Transmission electron microscopy (TEM) and Photon 
correlation spectroscopy 
 
TEM could reveal typical features of the triglyceride 
lattice such as planar layers in the SRMS. Photon corre-
lation spectroscopy (PCS) measurements may be 
performed with a Zetasizer. Figure 4 shows the TEM 











Figure 4. TEM micrographs of: (a) softisan 100 (bar= 303 nm), (b): SRMS 100 consisting of softisan 




micrographs of (a): softisan 100 (bar= 303 nm), (b): 
SRMS 100 consisting of softisan 100 and 50% of P90G 
(Friedrich and Müller-Goymann, 2003). 
 
 
Determination of drug solubility in the SRMS 
 
For investigations on drug solubilization in the SRMS, the 
drug is added to the melt of the SRMS and then solu-
bilized under stirring at a temperature used in formulating 
the SRMS and the solubility limit of the drugs in the 
SRMS melt determined both macroscopically and micro-
scopically. Also, solubility may correspond to the highest 
drug concentration at which a transparent melt is be 




TYPES OF SRMS-BASED DRUG DELIVERY SYSTEMS 
 
Solid lipid nanoparticles (SLN) 
 
Friedrich and Müller-Goymann (2003) studied the effect 
of lipid matrix composition, homogenization speed, 
surfactant composition on the properties of nanosu-
spensions. They found out that for production of SRMS-
based nanosuspensions, a polysorbate 80/SRMS ratio of 
1:5 is sufficient for particle size reduction. Homogeni-
zation on cold with resulting product temperatures far 
below the melting points (m.p.) of the systems causes 
broad particle size distributions. They also found that to 
achieve small nanoparticles with a narrow particle size 
distribution, homogenization on hot is not required. 
Instead, the suspension temperature has to be just near 
the m.p. for more flexibility of the solid lipids or for a 
partial melting. This could be controlled by varying the 
homogenization pressure at room temperature. A pres-
sure of 1000 bar results in a temperature near the m.p. of 
SRMS100 (formed with lecithin and softisan 100), that of 
1500 bar in a temperature near the SRMS142 (formed 
with lecithin and Softisn 154) m.p. They also concluded 
that an increase in transition temperature after production 
caused an increase in particle size because of particle 




Solid lipid microparticles (SLM) 
  
SLM based on SRMS have been developed recently in 
order to control the release of drugs. Nnamani et al. 
(2010) formulated SRMS142-based solid lipid micro-
particles of glibenclamide and the findings showed that 
SRMS142 generated an imperfect matrix with numerous 
spaces that accommodated glibenclamide in a concen-
tration-dependent manner up to 60.58%. The blood 
glucose–lowering effect of the SLMs was higher than that 
of a commercial sample. The results also showed that 
P90Gylated-softisan
®
 142 conjugate, otherwise referred 
to as SRMS142, have numerous advantages: wetting, 
solubilization, drug stabilization, emulsification, and modi-
fied release. Umeyor et al. (2012) also formulated SRMS-
based SLM for intramuscular administration of gentamicin. 
SRMS formulated with Phospholipon
®
 90G and softisan
®
 
154 were used to prepare gentamicin-loaded SLMs and 
results revealed high encapsulation efficiency of about 92% 




and sustained release of drug for once daily adminis-
tration were obtained. Momoh et al. (2012) also produced 
ibuprofen-loaded SLMs based on SRMS and reported 
sustained release properties in addition to good in vivo 
anti-inflammatory properties. Uronnachi et al. (2013) also 
worked on the pharmacokinetics and biodistribution of 
zidovudine loaded in a solidified reverse micellar delivery 
system and also reported good in vivo bioavailability of 
zidovudine in addition to controlled release properties. 
Chime et al. (2012 and 2013 a) worked on indomethacin-
loaded SLMs-based on SRMS 154 and diclofenac 
potassium-loaded SLMs based on SRMS 154. The 
results showed high encapsulation efficiency of up to 
90%, good loading capacity of SRMS, gastro protective 
potentials, enhanced in vivo bioavailability and good sus-
tained release properties for once daily administration 





Solid lipid tablets based on SRMS have recently been 
produced by molding (Umeyor et al., 2012 b; Chime et 
al., 2013 b). In this method, softisan
®
 154 and lecithin 
were utilized. The drug was dissolved or dispersed in the 
lipid matrix and tablets were produced by molding using 
tablet mold. Gentamicin oral tablets were been produced 
by this method using lipid matrix based on solidified 
reverse micellar solutions consisting of phospholipid and 
triglycerides (Umeyor et al., 2012b) and the results show 
that SRMS-based tablets containing gentamicin were 
successfully prepared by fusion melt-solidification method 
which is simple, reproducible, scalable and cheap 
(Umeyor et al., 2012b) and tablets exhibited sustained 
release properties. SRMS-based tablets could be an 
alternative to the conventional parenteral dosage form of 
gentamicin. Some non-steroidal anti-inflammatory drugs 
(NSAIDs) based on SRMS have also been produced 
(Chime et al., 2013b). Diclofenac potassium and 
indomethacin solid lipid tablets have been produced and 
results showed that the tablets had sustained release 
properties for once daily administration in addition to 
ulcer inhibition potentials. Diclofenac potassium tablets 
based on SRMS showed good hardness and friability 
profiles, sustained release properties and possessed 
good anti-inflammatory and anti-nociceptive/analgesic 
effects. The formulations also exhibited good gastro-pro-
tective properties, as it inhibited the ulcerogenic poten-
tials of diclofenac potassium by about 85% (Chime et al., 
2013b). The in vitro release profile of diclofenac potas-
sium tablet based on SRMS was comparable to the 
release profile of a market brand, coated diclofenac 
potassium. However, formulations showed higher sus-
tained drug release. Advantages of lipid based tablets 
include: low cost of ingredients, low cost of technologies 
(equipment and labour requirement for the production of 





tablets) and improved oral bioavailability and reduced 





Controlled release of SRMS-based suppositories con-
taining metoclopramide-HCl was formulated by Schneeweis 
and Müller-Goymann (2000). The SRMS consisted of 
70% Witepsol W35 and 30% (w:w) lecithin. A 1% (w/w) 
metoclopramide-HCl (MCP) was solubilizied in the 
SRMS. After melting and on contact with water or any 
physicological aqueous media the SRMS exihibits an 
application induced transformation into a semisolid 
system of liquid crystalline microstructure. Due to a low 
coefficient of diffusion in this mesophase a controlled 
release of the drug may be possible. The release profiles 
of the in vitro experiments showed zero order kinetics 
and a sustained release of the SRMS-suppositories 
(SRMS-supp.) in comparison with commercial suppose-
tories (Schneeweis and Müller-Goymann, 2000). 
 
 
Advantages of SRMS based carriers 
 
The advantages of SRMS include: 
 
1) Generally, SRMS offers controlled release of drug, 
thereby enhancing patients’ compliance and leading to 
better disease management and reduced toxicity. 
2) The formulations can be tailored to meet a wide range 
of product development. 
3) Feasibility of various administration routes. 
4) Enhanced in vivo bioavailability. 
5) Enhanced physical stability.  
6) High carrier capacity.  
7) Ease of formulation and scale up. 
8) Protects loaded liable drugs against drug degradation. 
 
 
Drug release from reverse micelles 
 
When the reverse micellar delivery system comes into 
contact with an external fluid of the environment such as 
water or other biological fluid, a burst or gradual release 
of the ionic amphiphiles may occur. A concurrent release 
of the additional ionic amphiphiles and the agent of 
interest follow. The ionic amphiphiles released dissolve in 
the aqueous fluid media forming ionic monomers. Upon 
release of agent(s) of interest, depending on the pre-
vailing pH of the fluid environment and the pKa of the 
chemical compound, ionised molecules are formed. 
These ions carry permanent charges opposite to that of 
the polar region of the ionic amphiphiles. The oppositely 
charged polar groups of the ionised agents of interest 
and amphiphiles attract each other. At some point when 





to the charged species in the aqueous fluid, aggregation 
and reverse micelle formation occurs. This point is 
believed to be the critical reverse micelle concentration 
(CMC) (Mac-Gregor and Markham, 2010). These reverse 
micelles, in the aqueous fluid environment, eventually 
form colloidal microemulsions. In the human gastro-
intesyinal tract (GIT), such reverse micelles are in direct 
contact with the lipophilic membranes of the absorbing 
mucosal cells. Due to the inherent lipophilicity of the outer 
surface of the reverse-micelles, they partition rapidly into 
these membranes, thereby facilitating absorption. Once 
the reverse micelles partition into the lipophilic mem-
brane, the concentration of the amphiphilic molecule 
component of the reverse micelles diminish below the 
CMC. The reverse micelles undergo disaggregation and 
release the polar agent within their core. The kinetics of 
transport and transmembrane release of these agents 
may be essentially zero order or near about zero order 







SRMS could safely deliver and sustain the release of 
drugs and has advantages over polymeric delivery 
systems. It is easy to formulate and scale up and is 
produced using completely biodegradable lipids. The 
materials required for the production of SRMS are rela-
tively  cheap  and  available  and could enhance patients’ 
compliance by reducing side effects and preventing 
repeated dosing. SRMS could also be used in formulating 
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